US2013344080A1PendingUtilityA1

PILR alpha Interactions and Methods of Modifying Same

52
Assignee: GENENTECH INCPriority: Dec 23, 2010Filed: Jun 19, 2013Published: Dec 26, 2013
Est. expiryDec 23, 2030(~4.4 yrs left)· nominal 20-yr term from priority
Inventors:Ali ZarrinYonglian Sun
C07K 2317/76A61K 39/3955G01N 33/566C07K 16/2803C07K 16/28
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for modulating the cell surface interaction between a ligand and PILR-alpha comprising contacting cells with an effective amount of an agent that may modulate the interaction between said ligand and PILR-alpha, wherein the ligand is selected from NPDC1, COLEC12, ETBR, CLEC4G, BR3, MAG, IL-2Ra, FceRII, LRRTM4, DAG1, APLP1, PTPRN, WDR31, PSS8, SIGLEC7 and IL15-RA. 
     
     
         2 . The method of  claim 1 , wherein the cells express PILR-alpha. 
     
     
         3 . The method of  claim 1 , wherein the cells express NPDC1. 
     
     
         4 . The method of  claim 1 , wherein the cells express COLEC12. 
     
     
         5 . The method of  claim 1 , wherein the cells express ETBR. 
     
     
         6 . The method of  claim 1 , wherein the cells express CLEC4G. 
     
     
         7 . The method of  claim 1 , wherein the cells express BR3. 
     
     
         8 . The method of  claim 1 , wherein the cells express MAG. 
     
     
         9 . The method of  claim 1 , wherein the cells express IL-2Ra. 
     
     
         10 . The method of  claim 1 , wherein the cells express FceRII. 
     
     
         11 . The method of  claim 1 , wherein the cells express LRRTM4. 
     
     
         12 . The method of  claim 1 , wherein the cells express DAG1. 
     
     
         13 . The method of  claim 1 , wherein the cells express APLP1. 
     
     
         14 . The method of  claim 1 , wherein the cells express PTPRN. 
     
     
         15 . The method of  claim 1 , wherein the cells express WDR31. 
     
     
         16 . The method of  claim 1 , wherein the cells express PSS8. 
     
     
         17 . The method of  claim 1 , wherein the cells express SIGLEC7. 
     
     
         18 . The method of  claim 1 , wherein the cells express IL15-RA. 
     
     
         19 . An agent for modulating the interaction between PILR-alpha and a ligand selected from NPDC1, COLEC12, ETBR, CLEC4G, BR3, MAG, IL-2Ra, FceRII, LRRTM4, DAG1, APLP1, PTPRN, WDR31, PSS8, SIGLEC7 and IL15-RA. 
     
     
         20 . A method for enhancing pathogen clearance in a subject comprising blocking the interaction between PILRa and a surface entry protein on the pathogen. 
     
     
         21 . The method of  claim 20  wherein the pathogen is selected from  Listeria , Herpes Simplex Virus-1,  Neisseria meningitis, Haemophius influenzae , group B  Streptococcus, Campylobacter jejuni, Staph aureus , and  Escherichia coli.

Join the waitlist — get patent alerts

Track US2013344080A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.